Although several biomarkers such as tumor mutational burden (TMB) and programmed cell death-Ligand 1 (PD-L1) have been shown to predict the efficacy of immunotherapy, some patients with TMB-high or PD-L1-high are still resistant to immunotherapy (Giroux Leprieur et al., 2017; Hellmann et al., 2018a; Hellmann et al., 2018b; Samstein et al., 2019; Herbst et al., 2020; Montesion et al., 2021). The gene discussed is CD274; the disease is neoplasm.